Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data

Executive Summary

Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.

You may also be interested in...



ADA 2022 Wrap Up: Iterative Progress On Glucose Control, No Big Surprises

The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.

Minute Insight: Abbott Is Planning To Combine Glucose And Ketone Measurement Into One Wearable

The company announced that it is developing a new biowearable device that will continuously monitor both glucose and ketone levels with one sensor.

Abbott Surprises Analysts With CE Mark For Freestyle Libre 3

The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT145498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel